[#DIV28SUPER] Early-Bird Registration and 20% Discount Ends TOMORROW: APA Div 28 Convention

APA Div28 Members, 

 

An updated 2018 APA Div28 program is attached.

 

Importantly, the early-bird registration and 20% discount ends TOMORROW. Register here: http://convention.apa.org/attend/pricing

 

See below for a reiteration of other relevant info.

 

Best wishes, 

Michael

 

Highlights:

- Multidisciplinary themes and approaches (collaborative programming with 14 other APA divisions, 4 APA groups and 2 NIH divisions)

- Primary and secondary symposia focused on opioids (4), cannabis/marijuana (4), nicotine/tobacco (2), psychedelics (1) and alcohol (1)

- Emphasis on translational and sex differences research

- Two primary symposia sponsored by the APA Central Programming Group focused on emerging clinical and research tools with live demonstrations (non-invasive brain stimulation and data crowdsourcing)

- Two networking/social hours

- Two collaborative poster sessions with Division 50 (addiction), NIDA and NIAAA (>100 posters total)

- Eight opportunities to earn continuing education credits

- The APA Social Hour for First-Time Attendees

- The APA Science at Sunset Poster Competition 

 

Other:

- Keyword search the entire convention program here: http://www.apa.org/convention/program-search.aspx?_ga=2.5664755.1782418109.1529507864-298983051.1515943711

- Stay connected with this handle: #APA2018

- Stay connected with the APA Convention App:

Apple: https://itunes.apple.com/us/app/american-psychological-association/id1007514352?ls=1&mt=8

Google Play: https://play.google.com/store/apps/details?id=com.coreapps.android.followme.apaconvention

- Visit the main convention website for additional information here: http://convention.apa.org

 

--------------------------------------------------------------------------

Michael J. Wesley, Ph.D.

Program Chair, Psychopharmacology and Substance Abuse

Mark Smith

President, Psychopharmacology and Substance Abuse

 

Assistant Professor and Director

Neurobehavioral Systems Lab

University of Kentucky College of Medicine

Department of Behavioral Science

 

Office: (859) 323-1332

Lab:    (859) 257-7444

 

CONFIDENTIALITY STATEMENT

The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at 859.323.1332 and delete this message and its attachments, if any. 

--------------------------------------------------------------------------

 

 

[#DIV28SUPER] HEALing Communities Study RFI

_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org
FYI...
https://www.gpo.gov/fdsys/pkg/FR-2018-06-29/pdf/2018-14031.pdf



_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] UVM NIH POSTDOCTORAL RESEARCH FELLOWSHIP POSITION

NIH Postdoctoral Research Fellowship Opportunity

 

The University of Vermont's Center on Behavior and Health announces an NIH postdoctoral research fellowship opportunity in our internationally recognized center of excellence for the study of substance abuse. The fellow will participate in the conduct of an ongoing NIDA/FDA-funded trial on the use of tobacco in vulnerable populations, as well as develop new research opportunities in related areas. The mentoring team has an exceptional track record of helping fellows further their careers as independent investigators.

 

Eligibility: Applicants must have completed their training in psychology, behavior analysis, or a related discipline and be U.S. citizens or permanent residents. Trainees are selected on the basis of scholastic record and commitment to a career in tobacco research. Individuals must be highly motivated, possess initiative and a desire to learn and expand their interests and expertise. Experience with behavioral economics is highly valued. Appointment:  2-3 yrs.

 

Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.

 

To apply: Send application form (downloaded from VCBH website), a cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Diann Gaalema c/o Ms. Marissa Wells (mwells2@uvm.edu). 

 

About us: The VCBH was established in 2013, sponsored in part by a Centers of Biomedical Research Excellence (COBRE) Award from the National Institute on General Medical Sciences and a Centers of Tobacco Regulatory Science (TCORS) Award from the National Institute on Drug Abuse. The VCBH resides within the College of Medicine at the University of Vermont, with the director and administrative offices being located within the Department of Psychiatry, and participating investigators, collaborators, and advisors across 15 academic departments in the College of Medicine and 7 colleges within UVM and 5 other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels. The focus of the VCBH is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk, and developing effective interventions and policies to promote healthy behavior.

 

For more information:  Contact Ms. Marissa Wells, mwells2@uvm.edu or see our website.

 

Burlington, Vermont is located in the beautiful Lake Champlain region, surrounded by the Green and Adirondack Mountains. It is a great place for families, boasting excellent schools and year-round recreational opportunities. It is home to the University of Vermont and many other colleges that provide an academically stimulating and culturally rich environment. Montreal and Boston are within easy driving distances.

--

Stephen T. Higgins, Ph.D.

Director, Vermont Center on Behavior and Health

Virginia H. Donaldson Professor of Translational Science

Departments of Psychiatry and Psychological Science

Vice Chair, Department of Psychiatry

University of Vermont

1 South Prospect Street

Burlington, VT  05401-1419

VCBH Administrator: Marissa Wells, MPH
mwells2@uvm.edu

802-656-0079

[#DIV28SUPER] Upcoming Psychopharmacology COnference

Dear all,

   Please see the attached program announcement for the Annual Fall Psychopharmacology Conference.

Thanks,

Alan

Alan Lincoln, Ph.D., MSCP, BCBA-D

Distinguished Professor

Interim Program Director:

   Postdoctoral MS in Clinical Psychopharmacology Program

California School of Professional Psychology
Alliant International University
10455 Pomerado Road, DH 101
San Diego, CA, USA 92131
858 635 4768    Fax 858 566-4356

The is electronic message transmission contains information from Alan Lincoln, PhD, MSCP, BCBA-D that may be confidential. The information is intended solely for the recipient and use by any other party is not authorized. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this information is prohibited.

If you received this electronic transmission in error, please notify me by telephone  619-994-3576 or this e-mail address. 

[#DIV28SUPER] Postdoctoral Research Fellowship

Posted on the behalf of Shanna Babalonis.

Postdoctoral Research Fellowship in Human Behavioral Pharmacology and Clinical Trials
University of Kentucky
College of Medicine
Center on Drug and Alcohol Research


The Center on Drug and Alcohol Research at the University of Kentucky is currently accepting applications for a postdoctoral research fellowship in human behavioral pharmacology. The applicant will have the opportunity to work with faculty in a highly collaborative environment and contribute to studies examining the abuse potential of opioids and cannabinoids, novel treatments for substance use disorders, and the impairing effects of various drugs in a simulated driving environment. There will also be opportunities to apply for a post-doctoral training position on one of two UK NIDA T32 Drug Abuse Research training grants.

Individuals with a Ph.D. in a relevant discipline (neuroscience, psychology, biomedical science, pharmacology) and research experience in drug abuse, clinical trials or human behavioral pharmacology are encouraged to apply. The appointment duration is 2-3 years. Salary and benefits are competitive and commensurate on experience.

Candidates are invited to submit their applications, complete with the following items:
1. A cover letter
2. A current curriculum vita (CV)
3. Graduate academic record (i.e., official transcript)
4. The names and contact information for three professional references

Application packets should be submitted via email to: Sharon Walsh, Ph.D. (sharon.walsh@uky.edu)

_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] Kratom public health and science in the context of the Opioid Overdose Crisis

Please post this open letter addressing an update on kratom science and public health perspectives to the Congressional Leadership. Thank you, Jack Henningfield and the 8 co-authors.

[#DIV28SUPER] APA Div28 2018 Convention Details

 

Dear APA Division 28 Members,

 

The 126th annual APA meeting is rapidly approaching (August 9-12, 2018, San Francisco, CA). On behalf of the current APA Division 28 President (Mark Smith) and Program Chair (myself), we are excited to present to you the 2018 Division 28 programming schedule (see attached).

 

Division 28 Program Highlights Include:  

- Multidisciplinary themes and approaches (collaborative programming with 14 other APA divisions, 4 APA groups and 2 NIH divisions)

- Primary and secondary symposia focused on opioids (4), cannabis/marijuana (4), nicotine/tobacco (2), psychedelics (1) and alcohol (1)

- Emphasis on translational and sex differences research

- Two primary symposia sponsored by the APA Central Programming Group focused on emerging clinical and research tools with live demonstrations (non-invasive brain stimulation and data crowdsourcing)

- Two networking/social hours

- Two collaborative poster sessions with Division 50 (addiction), NIDA and NIAAA (>100 posters total)

- Eight opportunities to earn continuing education credits

 

Division 28 is also participating in these special events:

- The APA Social Hour for First-Time Attendees

- The APA Science at Sunset Poster Competition

 

Other important notes:

- The early-bird registration deadline (save up to 20%) is a little over a week away. Register here: http://convention.apa.org/attend/pricing

- Keyword search the entire convention program here: http://www.apa.org/convention/program-search.aspx?_ga=2.5664755.1782418109.1529507864-298983051.1515943711

- Stay connected with this handle: #APA2018

- Stay connected with the APA Convention App (fyi, the reviews for these apps are not stellar but the website keyword search seems legit):

Apple: https://itunes.apple.com/us/app/american-psychological-association/id1007514352?ls=1&mt=8

            Google Play: https://play.google.com/store/apps/details?id=com.coreapps.android.followme.apaconvention

- Visit the main convention website for additional information here: http://convention.apa.org

 

If you have any program-related questions, concerns or comments, then please feel free to email me. We are looking forward to seeing you in San Francisco!

 

Warm regards,

Michael

 

--------------------------------------------------------------------------

Michael J. Wesley, Ph.D.

Program Chair, Psychopharmacology and Substance Abuse

Mark Smith

President, Psychopharmacology and Substance Abuse

 

Assistant Professor and Director

Neurobehavioral Systems Lab

University of Kentucky College of Medicine

Department of Behavioral Science

 

Office: (859) 323-1332

Lab:    (859) 257-7444

 

CONFIDENTIALITY STATEMENT

The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at 859.323.1332 and delete this message and its attachments, if any. 

--------------------------------------------------------------------------

 

Re: [#DIV28SUPER] Post-Doctoral Fellowship at the University of Kentucky

Hi

May I know how you got my name? 

On Mon, Jun 18, 2018 at 10:55 AM Stoops, William <wwstoo0@email.uky.edu> wrote:

Post-Doctoral Fellowship

** Available July 1, 2018 ***

The Laboratory of Human Behavioral Pharmacology at the University of Kentucky College of Medicine is seeking applicants for a post-doctoral fellowship. This is a two-year fellowship, with an optional third year, funded by the National Institute on Drug Abuse (NIDA) that is designed to train researchers in behavioral pharmacology and clinical trials in the treatment of drug use disorders. The fellowship also provides ample opportunity for professional development, including grant writing and enhancing presentation and publication skills. Applicants should be highly motivated, have recently obtained a doctorate in psychology, pharmacology or a related discipline and must be a U.S. citizen or permanent resident. The fellowship includes salary, tuition (if applicable) and expenses for travel to conferences.  

To Apply: Submit a cover letter stating your research interests along with CV and 3 letters of reference to: william.stoops@uky.edu. The application review begins immediately and will continue until the position is filled. This is a full-time position that is available starting July 1.  

For further inquiries, contact:

-Dr. Joshua A. Lile

Associate Professor, Department of Behavioral Science, University of Kentucky College of Medicine

jalile2@uky.edu

-Dr. Craig R. Rush

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

Crush2@email.uky.edu

-Dr. William W. Stoops

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

William.stoops@uky.edu

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

--

Shirin Tabib, PsyD.

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

Re: [#DIV28SUPER] Post-Doctoral Fellowship at the University of Kentucky

would you please provide me with the application link.

Thanks!

Dr. Ben E. Toubak, DMD,PsyD, MA, MPH. CAADAC

Neuropsychology Consultation,

Lead Learning Disability Specialist Counselor

Drug & Alcohol Counselor

Adjunct Faculty - Lecturer

On Monday, June 18, 2018, 10:55:15 AM PDT, Stoops, William <wwstoo0@EMAIL.UKY.EDU> wrote:

Post-Doctoral Fellowship

** Available July 1, 2018 ***

The Laboratory of Human Behavioral Pharmacology at the University of Kentucky College of Medicine is seeking applicants for a post-doctoral fellowship. This is a two-year fellowship, with an optional third year, funded by the National Institute on Drug Abuse (NIDA) that is designed to train researchers in behavioral pharmacology and clinical trials in the treatment of drug use disorders. The fellowship also provides ample opportunity for professional development, including grant writing and enhancing presentation and publication skills. Applicants should be highly motivated, have recently obtained a doctorate in psychology, pharmacology or a related discipline and must be a U.S. citizen or permanent resident. The fellowship includes salary, tuition (if applicable) and expenses for travel to conferences.  

To Apply: Submit a cover letter stating your research interests along with CV and 3 letters of reference to: william.stoops@uky.edu. The application review begins immediately and will continue until the position is filled. This is a full-time position that is available starting July 1.  

For further inquiries, contact:

-Dr. Joshua A. Lile

Associate Professor, Department of Behavioral Science, University of Kentucky College of Medicine

jalile2@uky.edu

-Dr. Craig R. Rush

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

Crush2@email.uky.edu

-Dr. William W. Stoops

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

William.stoops@uky.edu

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] Post-Doctoral Fellowship at the University of Kentucky

Post-Doctoral Fellowship

** Available July 1, 2018 ***

The Laboratory of Human Behavioral Pharmacology at the University of Kentucky College of Medicine is seeking applicants for a post-doctoral fellowship. This is a two-year fellowship, with an optional third year, funded by the National Institute on Drug Abuse (NIDA) that is designed to train researchers in behavioral pharmacology and clinical trials in the treatment of drug use disorders. The fellowship also provides ample opportunity for professional development, including grant writing and enhancing presentation and publication skills. Applicants should be highly motivated, have recently obtained a doctorate in psychology, pharmacology or a related discipline and must be a U.S. citizen or permanent resident. The fellowship includes salary, tuition (if applicable) and expenses for travel to conferences.  

To Apply: Submit a cover letter stating your research interests along with CV and 3 letters of reference to: william.stoops@uky.edu. The application review begins immediately and will continue until the position is filled. This is a full-time position that is available starting July 1.  

For further inquiries, contact:

-Dr. Joshua A. Lile

Associate Professor, Department of Behavioral Science, University of Kentucky College of Medicine

jalile2@uky.edu

-Dr. Craig R. Rush

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

Crush2@email.uky.edu

-Dr. William W. Stoops

Professor, Department of Behavioral Science, University of Kentucky College of Medicine

William.stoops@uky.edu

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

[#DIV28SUPER] Call for Papers

Call for Papers: Experimental and Clinical Psychopharmacology

 

Special Issue for April 2019 on:

Therapeutic and Abuse-Related Effects of Cannabis and Cannabinoids

 

This special issue will provide an overview of current research on cannabis and cannabinoids with an emphasis on issues related to their legalization for medical and recreational use.  We encourage submission of review articles and original research reports in this area, including the following topics: therapeutic efficacy of cannabis and cannabinoids across different disease conditions; etiology of cannabinoid use disorders; consequences of cannabinoid exposure during pregnancy, adolescence, and adulthood; development of forensic testing for detecting acute cannabis intoxication;  influence of route of cannabinoid administration on therapeutic effects and abuse liability;  variations in THC content across cannabis strains and cannabinoid-enriched products, and implications for use; current federal restrictions on cannabis research; prevalence of synthetic cannabinoids, issues with their regulation, mechanisms of action and consequences of their use; and changes in public perceptions of perceived harm of medicinal and recreational cannabis and cannabinoid use.

 

Researchers in this area may submit review articles or primary research reports to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (http://pha.edmgr.com/), and the cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue on Therapeutic and Abuse-Related Effects of Cannabis and Cannabinoids.  All submissions will undergo our normal peer review. Manuscripts received no later than October 1, 2018 will be considered for inclusion in the special issue. We strongly encourage individuals to contact the guest editors in advance with their ideas and a draft the title and abstract.

 

Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, Ashley Acheson, PhD, awacheson@uams.edu, or William Fantegrossi, wefantegrossi@uams.edu, or the Editor, William Stoops, PhD at william.stoops@uky.edu.

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

[#DIV28SUPER] Psychology Graduate study at Univ of Pittsburgh for underrepresented students

The Pitt Psychology Department is excited to announce the second year of our VIPitt program which is a two-day program for prospective graduate students who are racially and/or ethnically underrepresented students who are interested in graduate study and research in Psychology at Pitt. The program will be in October 2018, and the deadline for applications is July 1^st, 2018. 

Here’s the link with additional information:

 

https://psychology.pitt.edu/event/vipitt-weekend

 

The application is brief. The program has dual goals of helping students improve applications and interview skills, as well as giving them more information about Pitt in the hopes that they’ll consider applying to work with faculty here for their graduate work. We cover basically everything: travel to Pittsburgh, housing, meals, and transportation to and from the airport both in Pittsburgh and home towns.

 

Ken Perkins PhD

Univ of Pittsburgh

[#DIV28SUPER] Division 28 Social Happy Hour TONIGHT as Henry's Pub!

Division 28 Members – For those of you attending CPDD, please plan to attend our Social Happy Hour TONIGHT at Henry's Pub, and please advertise, recruit, and bring your non-Division 28 friends and colleagues to join the Division.  

 

Social Happy Hour and Bottomless Buffet

 

The Division of Psychopharmacology and Substance Abuse (Division 28) of the American Psychological Association invites our CPDD friends and colleagues interested in the Division to join us for a Social Happy Hour on Monday, June 11, 7:00 - 8:30 pm for drinks and a bottomless buffet.

 

All guests who elect to join the Division will receive two free drink tickets.

 

Henry's Pub

Gaslamp Quarter

(10-min walk from the Hilton)

618 5th Avenue
San Diego, CA 92101

 

The Division of Psychopharmacology and Substance Abuse is a professional organization established in 1966 as a division of the American Psychological Association. Its mission is to advance scientific knowledge and education on general psychopharmacology and the determinants and treatment of substance abuse. Our membership includes individuals from universities, medical schools, hospitals, government, industry, and private practice.

 

Annual membership fees are $20 for members, associates, and affiliates, and $9 for students. All guests who elect to join the Division will receive two free drink tickets ($14 value)

 

 

 

 

[#DIV28SUPER] 6th ANNUAL VERMONT CENTER ON BEHAVIOR AND HEALTH CONFERENCE

6^th Annual Conference

The U.S. Opioid Epidemic: The Need for Innovation and Greater Treatment Capacity

 

October 11-12, 2018

Burlington Hilton Hotel, Burlington, Vermont

 

The 6^th Annual VCBH Conference will focus on the nation's opioid epidemic, improving access to treatment, and effective pain/addiction management. These topics are among the major priorities of the U.S. Department of Health and Human Services, and the National Institutes of Health. Scholars from leading universities and medical centers will share their research and knowledge throughout the 2-day program.

 

This year's keynote speaker is Sharon Walsh, Ph.D., Director of the Center on Drug and Alcohol Research, and Professor of Behavioral Science at the University of Kentucky. Dr. Walsh focuses her research on pharmacological issues in opioid dependence and assessing novel treatments for opioid withdrawal.

 

We are also announcing the call for poster abstracts focused on research related to the opioid dependence epidemic. Abstracts will be evaluated on the basis of scientific merit. Please send submissions (including title, authors, affiliations, and 250-word abstract) to Diann Gaalema at diann.gaalema@med.uvm.edu by July 31.

For conference program, registration and hotel links, please visit our conference webpage. For general information, please contact Marissa Wells at mwells2@uvm.edu.

 

Can't attend the conference? Watch it LIVE at: https://livestream.com/VCBH/Conference2018

--

Stephen T. Higgins, Ph.D.

Director, Vermont Center on Behavior and Health

Virginia H. Donaldson Professor of Translational Science

Departments of Psychiatry and Psychological Science

Vice Chair, Department of Psychiatry

University of Vermont

1 South Prospect Street

Burlington, VT  05401-1419

VCBH Administrator: Marissa Wells, MPH
mwells2@uvm.edu

802-656-0079

[#DIV28SUPER] NIDA Neuroscience Update June 7, 2018

Table of Contents:

I.      NOT-DA-18-017 NIDA to Highlight Topics of Special and/or Continuing Interest in Addiction Research on the NIDA Website.  https://grants.nih.gov/grants/guide/notice-files/NOT-DA-18-017.html

 

II.   PAR-18-789 Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-18-789.html

III.    PAS-18-624 Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01- Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PAS-18-624.html 

 

 

NOT-DA-18-017 NIDA to Highlight Topics of Special and/or Continuing Interest in Addiction Research on the NIDA Website.  https://grants.nih.gov/grants/guide/notice-files/NOT-DA-18-017.html

NIDA is working to reduce the number of specialized Program Announcements (PA) published in the NIH Guide for Grants and Contracts to streamline the application process for our applicant community.  Rather than navigating a large number of specialized PAs, NIDA created a website (https://www.drugabuse.gov/funding/funding-priorities/nida-topics-specialcontinuing-interest-dat ) detailing the areas of science with the highest priority for NIDA that leverage parent FOAs to solicit topic-specific applications in these areas. This website will provide information to the research community all in one location. The NIDA Topics of Interests (DAT) site provides links to detailed descriptions of the scientific/research topics of interest, contact information for NIDA program staff with relevant expertise, as well as list of the most relevant parent FOAs that can be used to submit applications in these areas of interest. 
 
NIDA will continue to publish Requests for Applications (RFAs) and Program Announcements as needed to accommodate special receipt dates or review considerations.

---

 

II. PAR-18-789 Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-18-789.html

Application due dates: August 21, 2018, March 19, 2019; August 21, 2019, March 19, 2020; August 21, 2020, March 19, 2021, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Purpose:

The goals of this initiative are to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ genetic and genomics strategies. We also encourage applications that take genetic and/or genomics approaches to integrate data, delineate gene networks, and uncover the function of known or newly discovered genetic or epigenetic variants.

Investigators examining the phenotype of knockout mice are discouraged from submitting applications to this FOA. Instead, they should submit applications in response PA-17-155 (R01) PA-17-157 (R21) Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders.”

This FOA will replace PAR-15-120 "Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01)." 

-----

III. PAS-18-624 Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01- Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PAS-18-624.html 

 

Application due dates:  Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Purpose:

This funding opportunity announcement (FOA) invites innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate.

 

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309